Hypermethylated Genes of MicroRNA in Ovarian Carcinoma: Metastasis Prediction Marker Systems
- Авторы: Filippova E.1, Loginov V.1,2, Burdennyi A.1, Braga E.1,2, Pronina I.1, Kazubskaya T.3, Kushlinskii D.3, Utkin D.3, Fridman M.4, Khodyrev D.5, Kushlinskii N.3
-
Учреждения:
- Research Institute of General Pathology and Pathophysiology
- Research Center for Medical Genetics
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
- N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences
- Federal Scientific and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of the Russia
- Выпуск: Том 167, № 1 (2019)
- Страницы: 79-83
- Раздел: Oncology
- URL: https://journals.rcsi.science/0007-4888/article/view/241469
- DOI: https://doi.org/10.1007/s10517-019-04465-5
- ID: 241469
Цитировать
Аннотация
We identified a group of miRNA genes whose methylation is associated with ovarian cancer metastasis. Based on these data, new markers and the systems of markers predicting tumor dissemination were selected. Using methylation-specific PCR and a representative set of 54 ovarian cancer samples, we identified 10 microRNA genes (MIR-124a-2, MIR-127, MIR-125b-1, MIR-129-2, MIR-137, MIR-193a, MIR-203a, MIR-34b/c, MIR-130b, and MIR-1258) whose methylation is associated with tumor metastasis. The greatest association was established for 4 genes: MIR-137, MIR-193a, MIR-34b/c, and MIR-130b (p<0.01). ROC analysis revealed 3 most optimal marker systems including 4-5 miRNA genes and characterized by high sensitivity (82-94%) and specificity (76-86%) at AUC=0.89-0.92. Methylation of any three genes from these systems is sufficient to predict metastasis with the specified accuracy. Detection of the group of hypermethylated miRNA genes with predictive value for ovarian cancer metastasis is of great importance for personalized treatment of the patients.
Об авторах
E. Filippova
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow
V. Loginov
Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics
Email: eleonora10_45@mail.ru
Россия, Moscow; Moscow
A. Burdennyi
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow
E. Braga
Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics
Автор, ответственный за переписку.
Email: eleonora10_45@mail.ru
Россия, Moscow; Moscow
I. Pronina
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Россия, Moscow
T. Kazubskaya
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow
D. Kushlinskii
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow
D. Utkin
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow
M. Fridman
N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences
Email: eleonora10_45@mail.ru
Россия, Moscow
D. Khodyrev
Federal Scientific and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of the Russia
Email: eleonora10_45@mail.ru
Россия, Moscow
N. Kushlinskii
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Россия, Moscow